Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NUPAT-01: Neoadjuvant FOLFIRINOX vs GEM + nab-PTX in Borderline Resectable Pancreatic Cancer
NCT02717091Phase 2Unknown
- Sponsor
- Nagoya University
- Start
- Jul 2015
- Primary completion
- Jun 2020
- Modality
- DNA Intercalators/Alkylators, Orthosteric Ligands
01
Overview
Phase 2, randomised, open-label trial of fluorouracil, folinic acid, irinotecan, oxaliplatin, gemcitabine and 1 more in pancreatic ductal adenocarcinoma (PDAC) (2 arms), sponsored by Nagoya University. Primary endpoint: R0 Resection Rate at 3 months. Status: unknown.
02
Drugs
fluorouracilfolinic acidirinotecanoxaliplatingemcitabine
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT02717091.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02717091.